Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer: The VIOLETTA Trial

4. november 2026 opdateret af: CHIU Ka Fung Peter, Chinese University of Hong Kong

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer Using Organ Based Tracking (OBT) Navigation: The VIOLETTA Trial

This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

Studieoversigt

Detaljeret beskrivelse

This is a prospective multi-centre trial in 5 hospitals in 4 countries to investigate the efficacy and complications of TMA as a minimally invasive focal therapy for PCa. Men aged ≥50 with PSA < 20ng/mL, 1-2 MRI lesions with maximal dimension ≤15mm and ISUP grade group 2-3 PCa will be recruited. Transperineal TMA of the prostate tumor(s) will be done with repeated ablations by a single microwave needle guided by MRI-Ultrasound fusion and OBT navigation. The primary outcome is any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

110

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion criteria:

(i) Men aged ≥50 years old (ii) Life expectancy > 10 years upon recruitment (iii) Able to understand the trial and can provide informed and written consent, dated and signed before the enrollment and before any exam required by the trial (iv) Localized intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy (v) Organ-confined prostate cancer on MRI (vi) PSA < 20 ng/mL (vii) 1-2 MRI visible lesion present with maximal tumor dimension ≤15mm, with targeted biopsy showing:

  • ISUP grade group 2 or 3 PCa
  • Systematic biopsies showing grade group 1-3 PCa just next to the MRI lesion is allowed
  • Systematic biopsies showing grade group 1 PCa far away from the lesion is allowed

Exclusion criteria:

(i) Patients not fit for general or spinal anaesthesia (ii) Patients unfit for MRI exam or MR gadolinium contrast (e.g. estimated glomerular filtration rate (eGFR) of <50 ml/min) (iii) Patients with coagulopathy that cannot be corrected (iv) Patients on anticoagulants or antiplatelets that cannot be stopped (Low dose Aspirin, e.g. 80-100mg, is acceptable and no need to stop before or during TMA treatment) (v) Patients with previous treatment of prostate cancer (vi) Patients with prior pelvic radiotherapy for prostate cancer or other cancer (vii) Patients with maximal length of target lesion >15mm (viii) Patients with MRI lesion within 10mm from rectum or 10mm from sphincter on MRI (ix) Patients with >2 areas (MRI-visible or invisible) of prostate cancer (x) Patients with Gleason score 4+4 or any Gleason pattern 5 cancer (xi) Patients with systematic cores showing any Gleason 4 pattern PCa which are not adjacent to the target lesions (1 core of Gleason 3 pattern PCa on systematic cores in contralateral lobe is acceptable) (xii) Patients with definite extracapsular disease on imaging (prostate capsular contact without definite extra-capsular extension is acceptable) (xiii) Patients with bladder pathology including bladder stone or bladder cancer (xiv) Patients with known urethral stricture

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Targeted Microwave Ablation (TMA)

Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation

Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The oncological control of prostate cancer
Tidsramme: At 12 months after treatment

Any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months after treatment, defined by:

• ISUP grade group 2 or above PCa

At 12 months after treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinically significant cancer detection on biopsy of each ablated MRI visible lesion
Tidsramme: At 12 months after treatment

Per-lesion analysis of csPCa detected on biopsy of any ablated areas at 12 months

At 12 months after treatment
Cancer detection on biopsy of each ablated MRI invisible lesion
Tidsramme: At 12 months after treatment

Per-lesion analysis of any cancer detected on biopsy of any ablated areas at 12 months

At 12 months after treatment
Out-of-field recurrence: Any cancer outside treated area on systematic biopsy
Tidsramme: At 12 months after treatment

Out-of-field recurrence: Any cancer outside treated area on systematic biopsy

At 12 months after treatment
Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Tidsramme: At 3 Month, 6 Month and 12 Month

Complications of treatment using Common Terminology Criteria for Adverse Events (CTCAE) v5.0

At 3 Month, 6 Month and 12 Month
PSA change
Tidsramme: At baseline, 3 Month and 6 Month and 12 Month

PSA change after treatment

At baseline, 3 Month and 6 Month and 12 Month
Urinary Symptoms after treatment
Tidsramme: At baseline, 3 Month, 6 Month and 12 Month

Urinary symptoms measured by IPSS score, score ranging from 0-35 (the higher the worse)

At baseline, 3 Month, 6 Month and 12 Month
Sexual side effects after treatment
Tidsramme: At baseline, 3 Month, 6 Month and 12 Month

Sexual side effects, up to 1 year, measured by IIEF-5 score (ranging from 1-25), the lower the worse

At baseline, 3 Month, 6 Month and 12 Month
Continence side effects after treatment
Tidsramme: At baseline, 3 Month, 6 Month and 12 Month

Continence side effects, up to 1 year, measured by EPIC-26 questionnaire, the lower score the worse

At baseline, 3 Month, 6 Month and 12 Month
Common Terminology Criteria for Adverse Events (CTCAE) rectal toxicity
Tidsramme: At baseline, 3 Month, 6 Month and 12 Month

Rectal toxicity of treatment using Common Terminology Criteria for Adverse Events

At baseline, 3 Month, 6 Month and 12 Month
Quality of life measured by ED-5Q-5Lquestionnaire
Tidsramme: At baseline, 3 Month, 6 Month and 12 Month

Quality of life measured by ED-5Q-5L questionnaire, the higher the score the better in quality of life

At baseline, 3 Month, 6 Month and 12 Month
Quality of life in patients with prostate cancer measured by EPIC-26
Tidsramme: At baseline, 3 Month, 6 Month and 12 Month

Quality of life in patients with prostate cancer measured by EPIC-26 range 0-100, the higher score the better the quality of life

At baseline, 3 Month, 6 Month and 12 Month
Quality of life measured by QLQ-C30
Tidsramme: At baseline, 3 Month, 6 Month and 12 Month

Quality of life measured by QLQ-C30, score 0-100, the higher the score the better in quality of life

At baseline, 3 Month, 6 Month and 12 Month

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Peter Ka-Fung CHIU, PhD,MBChB, Chinese University of Hong Kong

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. marts 2024

Primær færdiggørelse (Anslået)

31. august 2029

Studieafslutning (Anslået)

31. oktober 2029

Datoer for studieregistrering

Først indsendt

21. januar 2024

Først indsendt, der opfyldte QC-kriterier

8. februar 2024

Først opslået (Faktiske)

16. februar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner